Paediatric αβ haploidentical transplantation (Pαβlo)

This is a prospective phase II study of the safety and cost-effectiveness of paediatric patients receiving TCR α+β+/CD19+ cell depleted haploidentical donor stem cell transplantation compared to those receiving an alternate donor haematopoietic stem cell transplant.
  • ·

Long term follow up data collection module

ACI, through BMT Network NSW, supported this pilot project. The aim is to review trends in long term care, identify opportunities for improvement in current clinical practice and inform strategic planning for long term follow up. The module was developed with reference to published international guidelines.
  • ·

Haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as GVHD prophylaxis

This phase II study will involve 6 transplant centres from Australia and New Zealand and is the ABMTRR's first prospective study. It is supported by a grant from the Arrow Bone Marrow Transplant Foundation, which enabled database enhancements to streamline data management for this and future registry studies.
  • ·

Autologous stem cell transplantation for testicular cancer

This retrospective study will assess survival outcomes for relapsed testicular cancer patients who underwent high dose chemotherapy stem cell transplantation across Australia and New Zealand in the years 1992-2017.
  • ·

Core binding factor AML in CR2 - survival after autologous transplant

The aim of this retrospective study is to provide clinicians and patients with an assessment of survival outcomes in CBF patients undergoing ASCT in CR2 and the potential impact of MRD status on outcome.
  • ·

Prophylactic early parenteral nutrition in BMT

This multicentre randomised controlled trial is an NHMRC funded study evaluating the effect of supplemental prophylactic early parenteral nutrition commenced prior to chemoradiotherapy compared to pragmatic standard nutrition care on disease free survival in patients about to commence conditioning chemoradiotherapy for allogeneic haematopoietic progenitor/stem cell transplantation. The ABMTRR will be providing long term outcome data for this study.
  • ·

Long term relative survival of haematopoietic stem cell transplant recipients

This project will review the 2002 to 2014 registry data, examining the patient and transplant characteristics and mortality outcomes after 2 and 5 years post–transplant. Comparisons will be made with the general population using relative survival methods.
  • ·

Non-relapse mortality in unrelated donor transplants

The number of unrelated donor transplants performed in Australia and New Zealand has increased markedly in the past 15 years. This retrospective analysis will examine the impact of changes in practice over this time, such as greater availability of fully matched donors, use of reduced intensity conditioning, graft vs host disease prophylaxis and supportive care.
  • ·

Effect of donor age on unrelated donor haematopoietic cell transplant outcome

This study will seek to determine the effect of donor age on the outcome of unrelated donor haematopoietic cell transplants in Australia, measured by engraftment, graft-versus-host disease, overall survival and disease-free survival.
  • ·

Prognostic implications of FLT3 and NPM1 mutations

In patients with AML, the karyotype at diagnosis is felt to provide the most important prognostic information in adults, however up to 50% of patients are reported to have a normal karyotype. In the normal karyotype group, molecular mutations, such as FLT3 and NPM1, may subdivide cytogenetically-normal AML (CN-AML) into prognostic subsets. Outcome data following allogeneic stem cell transplant in CN-AML has not previously been described in Australia.
  • ·

Conditioning for allogeneic transplants for paediatric patients with ALL

This ANZCHOG supported project will investigate the effect of the addition of thiotepa to total body irradiation and cyclophosphamide conditioning regimens, to determine whether there is any benefit to the use of thiotepa in conditioning for children transplanted for acute lymphoblastic leukaemia.
  • ·

The effect of genotype on transplant outcomes

This laboratory study is being done by Westmead Institute for Medical Research in conjunction with the ABMDR, analysing donor-recipient tissue samples. The ABMTRR is providing transplant outcome data so that the researchers can determine any effect of genotype on transplant outcome.

Update2018 Annual Data Summary is now available

lacomics.org